In 2001, the U.S. apheresis, hemostasis, and stem cell therapy products market totaled $580.2 million, a figure that is expected to more than double over the forecast period covered by this report.  Technologies such as blood modification, salvaging, and substitution; stem cell expansion and transplantation; and therapeutic apheresis will drive market growth.

This report from Medtech Insight presents a detailed overview of apheresis, hemostasis, and stem cell therapy technologies and markets, along with 15 company profiles.

Major topics include:  donor apheresis; therapeutic apheresis; blood disorders; metabolic disorders; blood substitutes; blood transfusions; plasma volume replacement; blood modifiers; blood salvaging; stem cell transplantations; stem cell expansion ex vivo; and umbilical cord blood collection.

TABLE OF CONTENTS

EXECUTIVE SUMMARY
     i. Introduction
     ii. Scope and Methodology
     iii. The Apheresis Products Market
     iv. The Hemostasis Products Market
     v. The Stem Cell Therapy Products Market
     vi. Total Market Forecast

1. APHERESIS PRODUCTS MARKET
     1.1 Apheresis
           1.1.1 Donor Apheresis
           1.1.2 Therapeutic Apheresis
      1.2 Apheresis Applications
           1.2.1 Platelet Therapy
           1.2.2 Plasmapheresis
           1.2.3 Erythrocytapheresis
           1.2.4 Leukoreduction
     1.3 Safety
     1.4 Costs
    1.5 Disadvantages of Single-Donor Collections
     1.6 Therapeutic Apheresis
          1.6.1 Types
                  1.6.1.1 Cytapheresis
                  1.6.1.2 Erythrocytapheresis
                  1.6.1.3 Extracorporeal Photophoresis
                            1.6.1.3.1 Development
                             1.6.1.3.2 Technique
                             1.6.1.3.3 Current and Developing Indications
                  1.6.1.4 Leukapheresis
                  1.6.1.5 Plasmapheresis
                  1.6.1.6 Therapeutic Phlebotomy
                  1.6.1.7 Thrombocytapheresis
          1.6.2 Indications and Protocols
                  1.6.2.1 Neurologic Conditions
                            1.6.2.1.1 Amyotrophic Lateral Sclerosis
                            1.6.2.1.2 Chronic Inflammatory Demyelinating
                                         Polyneuropathy
                            1.6.2.1.3 Guillain-Barré Syndrome
                            1.6.2.1.4 Multiple Sclerosis
                            1.6.2.1.5 Myasthenia Gravis
                  1.6.2.2 Blood Disorders
                            1.6.2.2.1 Autoimmune Hemolytic Anemia
                            1.6.2.2.2 Cutaneous T-Cell Lymphoma
                            1.6.2.2.3 Hematologic Malignancy
                            1.6.2.2.4 Hemolytic Uremic Syndrome
                            1.6.2.2.5 Hemophilia
                            1.6.2.2.6 Idiopathic Thrombocytopenia Purpura
                            1.6.2.2.7 Neonatal Hemolytic Disease
                            1.6.2.2.8 Paraproteinemia
                            1.6.2.2.9 Sickle Cell Anemia
                            1.6.2.2.10 Thrombotic Thrombocytopenia Purpura
                  1.6.2.3 Renal Disease
                            1.6.2.3.1 Goodpasture’s Syndrome
                            1.6.2.3.2 Immune-Complex Nephritis
                            1.6.2.3.3 Renal Transplantation
                  1.6.2.4 Rheumatic Disease
                            1.6.2.4.1 Systemic Lupus Erythematosus
                            1.6.2.4.2 Rheumatoid Arthritis
                            1.6.2.4.3 Inflammatory Myositis
                  1.6.2.5 Metabolic Disorders
                            1.6.2.5.1 Hyperlipidemia
                            1.6.2.5.2 Refsum’s Disease
                            1.6.2.5.3 Age-Related Macular Degeneration
          1.6.3 Reimbursement
     1.7 Products
          1.7.1 Current Equipment Technology
                  1.7.1.1 Centrifugation Systems
                  1.7.1.2 Membrane Filtration Systems
          1.7.2 Technological Developments
                  1.7.2.1 Adsorption Devices
                  1.7.2.2 Elutriation Systems
                  1.7.2.3 Ultrafiltration
     1.8 Trends in Apheresis Procedures
          1.8.1 Donor Apheresis
          1.8.2 Therapeutic Apheresis
     1.9 Market Forecast
     1.10 Market Analysis

2. THE HEMOSTASIS PRODUCTS MARKET
     2.1 Blood Supply
          2.1.1 Paid Donors
          2.1.2 Blood Safety
                  2.1.2.1 Products
     2.2 Blood Components
          2.2.1 Whole Blood
          2.2.2 Red Blood Cells
          2.2.3 Platelets
                  2.2.3.1 Supply
          2.2.4 Plasma
          2.2.5 Human Serum Albumin
          2.2.6 Human Immunoglobulin
          2.2.7 Cryoprecipitate/Coagulation Factors
     2.3 Blood Collection
     2.4 Blood Transfusions
          2.4.1 Autotransfusion
          2.4.2 Number of Transfusions
          2.4.3 Surgery and Transfusions
          2.4.4 Blood Screening
     2.5 Blood Substitutes
          2.5.1 Blood Substitute Technology
          2.5.2 Products in Development
                  2.5.2.1 Alliance Pharmaceutical
                  2.5.2.2 Baxter International
                  2.5.2.3 Biopure
                  2.5.2.4 Enzon
                  2.5.2.5 Hemosol
                  2.5.2.6 Northfield Laboratories
                  2.5.2.7 Sonus Pharmaceuticals
                  2.5.2.8 Synthetic Blood International
          2.5.3 Market Forecast
     2.6 Plasma Volume Replacement Products
          2.6.1 Colloid Solutions
                  2.6.1.1 Albumin
                  2.6.1.2 Dextran
                  2.6.1.3 Gelatin
                  2.6.1.4 Hydroxyethyl Starch
                  2.6.1.5 Plasma Protein Fraction
          2.6.2 Crystalloid Solutions
                  2.6.2.1 Dextrose Solution
                  2.6.2.2 Hartmann’s Solution
                  2.6.2.3 Normal Saline
          2.6.3 Guidelines
          2.6.4 Manufacturers
                  2.6.4.1 Abbott Laboratories
                  2.6.4.2 Instituto Grifols
                  2.6.4.3 ZLB BioPlasma/CSL
          2.6.5 Recombinant Human Serum Albumin
          2.6.6 Market Forecast
     2.7 Blood Modifiers
          2.7.1 Anticoagulants
                  2.7.1.1 Heparin
                            2.7.1.1.1 Indications
                  2.7.1.2 Warfarin
                            2.7.1.2.1 Indications
                  2.7.1.3 Anticoagulant Products
          2.7.2 Hemophilia
                  2.7.2.1 Treatment
                  2.7.2.2 Factor VIII Inhibitors
                  2.7.2.3 Factor VIII
                  2.7.2.4 Recombinant Factor VIII
                  2.7.2.5 Factor IX
                  2.7.2.6 Factor VIIa
          2.7.3 Antiplatelet Agents
                  2.7.3.1 Plavix
                  2.7.3.2 Persantine
                  2.7.3.3 Ticlid
                  2.7.3.4 ReoPro
                  2.7.3.5 Aggrastat
                  2.7.3.6 Integrilin
          2.7.4 Colony Stimulating Factor
                  2.7.4.1 Neutropenia
                  2.7.4.2 Colony Stimulating Factor Agents
          2.7.5 Hematinic Agents
                  2.7.5.1 Cyanocobalamin
                  2.7.5.2 Anabolic Steroids
                  2.7.5.3 Folates
                  2.7.5.4 Iron
                  2.7.5.5 Erythropoietin
                  2.7.5.6 Thrombopoietin Growth Factor
          2.7.6 Immunoglobulins
                  2.7.6.1 Costs
                  2.7.6.2 Shortages
          2.7.7 Hemorheologic Agents
                  2.7.7.1 Treatment
                  2.7.7.2 Treatment Agents
          2.7.8 Hemostatics and Antifibrinolytic Agents
                  2.7.8.1 Antifibrinolytic Amino Acids
                  2.7.8.2 Desmopressin
                  2.7.8.3 Aprotinin
          2.7.9 Thrombolytic Agents
                  2.7.9.1 Streptokinase
                  2.7.9.2 Urokinase
                  2.7.9.3 Tissue Plasminogen Activator
                             2.7.9.3.1 Disadvantages
          2.7.10 Vitamin K
          2.7.11 Market Analysis
          2.7.12 Market Forecast
     2.8 Blood Salvaging
          2.8.1 Technology
          2.8.2 Applications
          2.8.3 Risks
          2.8.4 Products
          2.8.5 Market Forecast

3. THE STEM CELL THERAPY PRODUCTS MARKET
     3.1 Sources and Types of Stem Cells
     3.2 Blood Cell Formation
          3.2.1 Embryonic Stem Cells
                  3.2.1.1 Federal Funding
     3.3 Stem Cell Transplantations
          3.3.1 Bone Marrow Transplantations
                  3.3.1.1 Limitations
          3.3.2 Peripheral Blood Stem Cell Transplantation
                  3.3.2.1 Advantages and Disadvantages
                  3.3.2.2 Collection, Storage, and Preparation
                  3.3.2.3 Mobilized Peripheral Blood
                  3.3.2.4 Infusion
          3.3.3 Umbilical Cord Blood Transplantations
     3.4 Stem Cell Selection and Cell Purging
          3.4.1 Depletion Strategies
          3.4.2 Positive Selection Techniques
          3.4.3 Clinical Outcomes
     3.5 Stem Cell Therapies
          3.5.1 Cancer
                  3.5.1.1 Breast Cancer
          3.5.2 Genetic Disorders
          3.5.3 Heart Disease
          3.5.4 Diabetes
          3.5.5 Autoimmune Disorders
          3.5.6 Immunodeficiencies
          3.5.7 Diagnosis and Immunization
          3.5.8 Organ Transplantation
                  3.5.8.1 Xenotransplantation
                            3.5.8.1.1 Limitations
     3.6 Stem Cell Transplantation, Procedure Volumes
     3.7 Minitransplantation
     3.8 Technological Aspects
          3.8.1 Companies and Products
                  3.8.1.1 Baxter International
                  3.8.1.2 CellPro
                  3.8.1.3 Gambro
                  3.8.1.4 Miltenyi Biotec/AmCell
                  3.8.1.5 Market Analysis
                  3.8.1.6 Market Forecast
          3.8.2 Stem Cell Expansion Ex Vivo
                  3.8.2.1 Applications
                  3.8.2.2 Culture Conditions
                  3.8.2.3 Biotechnology
                  3.8.2.4 Serum-Free Culture
                  3.8.2.5 Bioreactors
                            3.8.2.5.1 Flat Bed Perfusion Systems
                            3.8.2.5.2 Hollow-Fiber Bioreactors
                            3.8.2.5.3 Suspension Culture Systems
                  3.8.2.6 Companies and Products
                            3.8.2.6.1 Aastrom Biosciences
                            3.8.2.6.2 Cytomatrix
                            3.8.2.6.3 Tissue Therapeutics/Montec Research
                            3.8.2.6.4 Viacell
                  3.8.2.7 Market Analysis
          3.8.3 Umbilical Cord Blood
                  3.8.3.1 Collection and Storage
                  3.8.3.2 Private Versus Donor
                  3.8.3.3 Private Storage
                            3.8.3.3.1 Costs
                  3.8.3.4 Market Analysis
                  3.8.3.5 Market Forecast

4. COMPANY PROFILES

     4.1 Aastrom Biosciences, Inc.
     4.2 Abbott Laboratories, Inc.
     4.3 Alliance Pharmaceutical Corporation
     4.4 Amgen, Inc.
     4.5 AstraZeneca Group
     4.6 Aventis, Inc.
     4.7 Baxter International, Inc.
     4.8 Bayer AG
     4.9 Biopure Corporation
     4.10 Bristol-Myers Squibb Company
     4.11 COBE Cardiovascular, Inc./SNIA Group
     4.12 Fresenius HemoCare, Inc./Fresenius Medical Care AG
     4.13 Haemonetics Corporation
     4.14 Pharmacia Corporation
     4.15 Wyeth, Inc.

COMPANY LISTING

LIST OF EXHIBITS

Exhibit ES-1:  Advantages and Disadvantages of Apheresis Platelets 

Exhibit ES-2:  Apheresis Equipment and Disposables, Market Forecast,
                   2001-2007

Exhibit ES-3:  Blood Demand, by Condition/Procedure 

Exhibit ES-4:  Hemostasis Products, Market Forecast, 2001-2007 

Exhibit ES-5:  Advantages and Disadvantages of Stem Cells, by Source 

Exhibit ES-6:  Stem Cell Therapy Products, Market Forecast, 2001-2007 

Exhibit ES-7:  Apheresis, Hemostasis, and Stem Cell Therapy Products, Market
                   Forecast, 2002 and 2007

Exhibit 1-1:    Whole-Blood Platelets Versus Apheresis Platelets 

Exhibit 1-2:    Advantages and Disadvantages of Apheresis Platelets 

Exhibit 1-3:    Leukoreduced Blood Products, Cost Forecast, 2001-2007 

Exhibit 1-4:    2001, Blood Product Reimbursement Rates 

Exhibit 1-5:    Procedure Times for Manual and Apheresis Blood Collection
                    Procedures

Exhibit 1-6:    Apheresis Donation Interval Guidelines 

Exhibit 1-7:    Goals of Therapeutic Apheresis, by Type 

Exhibit 1-8:    Therapeutic Apheresis Categories 

Exhibit 1-9:    Guidelines for Therapeutic Apheresis, by Disease 

Exhibit 1-10:  Apheresis Recommendations for Neurologic Conditions 

Exhibit 1-11:  2001, United States Patient Registrants for Kidney and
                   Kidney-Pancreas Transplants

Exhibit 1-12:  2001, Kidney and Kidney-Pancreas Transplantation Survival 
                   Rates 

Exhibit 1-13:  Therapeutic Apheresis Indications Covered by Medicare 

Exhibit 1-14:  2002, Apheresis Centrifugation Systems 

Exhibit 1-15:  2002, Hollow-Fiber Membrane Filtration Systems 

Exhibit 1-16:  Therapeutic Apheresis Systems, by Technique 

Exhibit 1-17:  Apheresis, Procedure Volumes Forecast, by Type, 2001-2007

Exhibit 1-18:  Donor Apheresis, Procedure Volumes Forecast, 2001-2007 

Exhibit 1-19:  Therapeutic Apheresis, Procedure Volumes Forecast, 2001-2007

Exhibit 1-20:  Apheresis Equipment and Disposables, Market Forecast,
                   2001-2007

Exhibit 1-21:  2001, Apheresis Equipment and Disposables Market, Share
                   by Supplier

Exhibit 2-1:    Blood Demand, by Condition/Procedure 

Exhibit 2-2:    Recommendations For Use of Immunoglobulin Intravenous, by
                   Source

Exhibit 2-3:    Blood Collection, Procedure Volumes Forecast, 2001-2007 

Exhibit 2-4:    Blood Transfusion, Procedure Volumes Forecast, 2001-2007

Exhibit 2-5:    2002, Selected Blood Substitute Products 

Exhibit 2-6:    Blood Substitute Products, Market Forecast, 2001-2007 

Exhibit 2-7:    2001, Blood Substitution Incidence, by Condition 

Exhibit 2-8:    2002, Selected Plasma Volume Replacement Products, by
                   Indication

Exhibit 2-9:    2002, Selected Plasma Volume Expanders 

Exhibit 2-10:  Plasma Volume Replacement Products, Market Forecast,
                   2001-2007

Exhibit 2-11:  2002, Indications for Heparin Therapy 

Exhibit 2-12:  Indications for Warfarin Therapy 

Exhibit 2-13:  2002, Selected Factor VIII Products 

Exhibit 2-14:  2002, Selected Factor IX Products 

Exhibit 2-15:  2002, Selected Antiplatelet Agents 

Exhibit 2-16:  2002, Advantages of Plavix 

Exhibit 2-17:  2002, Populations at Risk for Developing Neutropenia 

Exhibit 2-18:  2002, Selected Immunoglobulin Intravenous Products 

Exhibit 2-19:  Risk Factors for Peripheral Artery Disease 

Exhibit 2-20:  Indications for Antifibrinolytic Therapy 

Exhibit 2-21:  Indications for Desmopressin Therapy 

Exhibit 2-22:  Indications for Thrombolytic Agent Therapy 

Exhibit 2-23:  2001, Blood Modifiers Market, Share by Supplier 

Exhibit 2-24:  Blood Modifiers, Market Forecast, 2001-2007 

Exhibit 2-25:  Selected Surgical Applications for Blood Salvaging 

Exhibit 2-26:  Blood Salvaging Products, Market Forecast, 2001-2007 

Exhibit 3-1:    Advantages and Disadvantages of Stem Cells, by Source 

Exhibit 3-2:    2002, Registered Stem Cell Institutions 

Exhibit 3-3:    Malignant Disorders Treated Using Bone Marrow Transplantation

Exhibit 3-4:    Advantages and Disadvantages of Bone Marrow Transplantation,
                    by Type

Exhibit 3-5:    2002, Techniques Used for Purging Stem Cells of Tumor Cells

Exhibit 3-6:    Bone Marrow Versus Peripheral Blood Stem Cell Transplantation

Exhibit 3-7:    Indications for Allogenic and Autologous Stem Cell Therapy 

Exhibit 3-8:    Gene-Modified Stem Cell Therapy Applications for Genetic
                   Disorders

Exhibit 3-9:    2001, Number of Patients on the National Patient Waiting List for
                   Organ Transplantation

Exhibit 3-10:  Stem Cell Transplantation, Procedure Volumes Forecast, by Type,
                   2001-2007

Exhibit 3-11:  Stem Cell Transplantation, Procedure Volumes Forecast, by
                   Disease, 2001-2007

Exhibit 3-12:  2002, Selected Stem Cell Extraction Devices 

Exhibit 3-13:  Stem Cell Extractors and Disposables, Market Forecast, 
                   2001-2007

Exhibit 3-14:  2002, Aastrom Biosciences, Hematopoietic Stem Cell Product
                   Pipeline

Exhibit 3-15:  Advantages and Disadvantages of Using Umbilical Cord Blood as
                   a Source Material for Stem Cells

Exhibit 3-16:  2001, Private Umbilical Cord Blood Banking Market, Share by
                   Supplier

Exhibit 3-17:  Umbilical Cord Blood, Unit Volumes Forecast, 2001-2007 

Exhibit 3-18:  Umbilical Cord Blood Products, Market Forecast, 2001-2007